Capsugel's Scintigraphic In Vivo Study of DRcaps Capsules Tracks Successful Delayed Release
Capsugel, a global leader in innovative dosage forms and solutions for the healthcare industry, has announced that the results of its 2013 scintigraphic in vivo study of its DRcaps capsules definitively documents that the specially formulated acid-resistant hydroxypropyl methylcellulose (HPMC) capsules are an “excellent choice” for delayed delivery of acid-sensitive ingredients such as probiotics and enzymes.
Data and images empirically demonstrate the capsules’ effective protection from early activation caused by stomach acids and, for a majority of study subjects, complete release in intestines where products such as probiotics and enzymes work best. More specifically, the capsules began release in a mean time of 52 min after ingestion and completely released the ingredients in a mean time of 72 min after ingestion.
“The results from this human clinical study provide scientific evidence of DRcaps capsules’ acid-resistant and delayed-release performance to give confidence that DRcaps capsules are an excellent choice for delivery of acid-sensitive ingredients,” said Dr Keith Hutchison, Senior Vice President of R&D at Capsugel.
The study was designed to investigate the in vivo behavior of DRcaps using a scintigraphic method to assess the gastrointestinal transit and release of the contents from capsules based on the images obtained. Gamma scintigraphy is an established technique in which a radio label is swallowed and the disposition in the gut is photographed externally over time.
The scintigraphic study revealed that the capsules actually began releasing at 52 min when they were about to leave the stomach. “That is 45 min later than an immediate release capsule and means that the contents of the capsules would often be released in the intestines — where probiotics and enzyme ingredients are most effective,” Dr Hutchison elaborated.
DRcaps capsules are designed with unique polymer properties to slow down capsule opening after swallowing without adding synthetic chemicals, solvents or other coating ingredients. “The special release properties built into the capsules provide the choice of a vegetarian product for fast product launches, and still provide acid-protection and delayed release,” Dr Hutchison concluded.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.